Wu Z, Young N
Blood. 2023; 142(14):1193-1207.
PMID: 37478398
PMC: 10644099.
DOI: 10.1182/blood.2022018581.
Ma J, Ge Z
Front Pharmacol. 2021; 12:701690.
PMID: 34483903
PMC: 8416074.
DOI: 10.3389/fphar.2021.701690.
Poon Z, Dighe N, Venkatesan S, Cheung A, Fan X, Bari S
Leukemia. 2018; 33(6):1487-1500.
PMID: 30575819
PMC: 6756222.
DOI: 10.1038/s41375-018-0310-y.
Hunter A, Zhang L, Padron E
Curr Treat Options Oncol. 2018; 19(12):67.
PMID: 30367269
DOI: 10.1007/s11864-018-0581-6.
Gao C, Wang J, Li Y, Zhao H, Li R, Hou L
Medicine (Baltimore). 2018; 97(34):e11860.
PMID: 30142779
PMC: 6112947.
DOI: 10.1097/MD.0000000000011860.
Myelodysplastic syndromes current treatment algorithm 2018.
Steensma D
Blood Cancer J. 2018; 8(5):47.
PMID: 29795386
PMC: 5967332.
DOI: 10.1038/s41408-018-0085-4.
Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
Brunner A, Steensma D
Clin Adv Hematol Oncol. 2018; 16(1):56-66.
PMID: 29741506
PMC: 6629038.
A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.
Yao C, Chen C, Huang H, Hou H, Lin C, Tseng M
Blood Adv. 2018; 1(19):1505-1516.
PMID: 29296792
PMC: 5728469.
DOI: 10.1182/bloodadvances.2017008284.
Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.
Shahrabi S, Khosravi A, Shahjahani M, Rahim F, Saki N
Oncol Rev. 2017; 10(2):311.
PMID: 28058097
PMC: 5178845.
DOI: 10.4081/oncol.2016.311.
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.
Della Porta M, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E
J Clin Oncol. 2016; 34(30):3627-3637.
PMID: 27601546
PMC: 6366344.
DOI: 10.1200/JCO.2016.67.3616.
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S, Vincelette N, Abraham I, Robertson K, Fernandez-Zapico M, Patnaik M
Clin Epigenetics. 2016; 8:68.
PMID: 27307795
PMC: 4908810.
DOI: 10.1186/s13148-016-0233-2.
[Clinical and laboratory characteristics in patients of myelodysplastic syndrome with PNH clones].
Li Y, Qin T, Xu Z, Zhang Y, Wang J, Li B
Zhonghua Xue Ye Xue Za Zhi. 2016; 37(4):313-7.
PMID: 27093995
PMC: 7343090.
DOI: 10.3760/cma.j.issn.0253-2727.2016.04.013.
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Prebet T, Sun Z, Ketterling R, Zeidan A, Greenberg P, Herman J
Br J Haematol. 2015; 172(3):384-91.
PMID: 26577691
PMC: 4794257.
DOI: 10.1111/bjh.13832.
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D
Ann Hematol. 2015; 94(12):1981-9.
PMID: 26410352
PMC: 4604495.
DOI: 10.1007/s00277-015-2486-9.
Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.
Zhou T, Kinney M, Scott L, Zinkel S, Rebel V
Blood. 2015; 126(9):1057-68.
PMID: 26077396
PMC: 4551359.
DOI: 10.1182/blood-2015-01-624239.
Stopping higher-risk myelodysplastic syndrome in its tracks.
Pollyea D, Gutman J
Curr Hematol Malig Rep. 2014; 9(4):421-31.
PMID: 25208927
DOI: 10.1007/s11899-014-0234-1.
Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
Uchida N, Hsieh M, Platner C, Saunthararajah Y, Tisdale J
PLoS One. 2014; 9(8):e104022.
PMID: 25089909
PMC: 4121241.
DOI: 10.1371/journal.pone.0104022.
Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris C, Gao J
Blood. 2014; 124(5):780-90.
PMID: 24891322
PMC: 4118486.
DOI: 10.1182/blood-2014-01-552463.
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Prebet T, Sun Z, Figueroa M, Ketterling R, Melnick A, Greenberg P
J Clin Oncol. 2014; 32(12):1242-8.
PMID: 24663049
PMC: 3986386.
DOI: 10.1200/JCO.2013.50.3102.
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.
Hu X, Wei H, Xiang L, Chertov O, Wayne A, Bera T
Leuk Res. 2013; 37(11):1551-6.
PMID: 24070652
PMC: 3818433.
DOI: 10.1016/j.leukres.2013.08.005.
